CAMPBELLVILLE, ON, July 18 /CNW/ - NIR Diagnostics Inc. (TSX Venture: NID - News), a leading-edge developer of handheld spectroscopy based medical instruments, announced today that it has achieved a level of accuracy in sponsored feasibility testing of its light-based in vitro glucose monitoring device that is sufficient to advance to development of a prototype and initiate clinical trials. The prototype will include hardware enhancements scheduled to be made by the Company’s contract manufacturing and supply partner, Boehringer Ingelheim microParts GmbH.
